130 related articles for article (PubMed ID: 11992628)
1. Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Cummings J; Boyd G; Ethell BT; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
Biochem Pharmacol; 2002 Feb; 63(4):607-13. PubMed ID: 11992628
[TBL] [Abstract][Full Text] [Related]
2. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Cummings J; Zelcer N; Allen JD; Yao D; Boyd G; Maliepaard M; Friedberg TH; Smyth JF; Jodrell DI
Biochem Pharmacol; 2004 Jan; 67(1):31-9. PubMed ID: 14667926
[TBL] [Abstract][Full Text] [Related]
3. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Cummings J; Ethell BT; Jardine L; Boyd G; Macpherson JS; Burchell B; Smyth JF; Jodrell DI
Cancer Res; 2003 Dec; 63(23):8443-50. PubMed ID: 14679008
[TBL] [Abstract][Full Text] [Related]
4. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.
Cummings J; Ethell BT; Jardine L; Burchell B
Anticancer Res; 2006; 26(3B):2189-96. PubMed ID: 16821585
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505.
Cummings J; Meikle I; Macpherson JS; Smyth JF
Anticancer Drug Des; 1996 Jul; 11(5):367-82. PubMed ID: 8765530
[TBL] [Abstract][Full Text] [Related]
6. Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
Cummings J; Meikle I; Macpherson JS; Smyth JF
J Chromatogr B Biomed Appl; 1996 Oct; 685(1):159-64. PubMed ID: 8930764
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
8. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R
Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
Meikle I; Cummings J; Macpherson JS; Smyth JF
Br J Cancer; 1996 Aug; 74(3):374-9. PubMed ID: 8695351
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing the cellular accumulation of SN-38 and camptothecin.
Cummings J; Boyd G; Macpherson JS; Wolf H; Smith G; Smyth JF; Jodrell DI
Cancer Chemother Pharmacol; 2002 Mar; 49(3):194-200. PubMed ID: 11935211
[TBL] [Abstract][Full Text] [Related]
11. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
[TBL] [Abstract][Full Text] [Related]
12. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
[TBL] [Abstract][Full Text] [Related]
13. Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.
Crews KR; Stewart CF; Jones-Wallace D; Thompson SJ; Houghton PJ; Heideman RL; Fouladi M; Bowers DC; Chintagumpala MM; Gajjar A
Clin Cancer Res; 2002 Jul; 8(7):2202-9. PubMed ID: 12114421
[TBL] [Abstract][Full Text] [Related]
14. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines.
Macpherson JS; Cummings J; Meikle I; Miller EP; Smyth JF
Eur J Cancer; 1997 Feb; 33(2):280-3. PubMed ID: 9135500
[TBL] [Abstract][Full Text] [Related]
16. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug MonoTherapy) strategy.
Angenault S; Thirot S; Schmidt F; Monneret C; Pfeiffer B; Renard P
Bioorg Med Chem Lett; 2003 Mar; 13(5):947-50. PubMed ID: 12617927
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate.
Narita M; Nagai E; Hagiwara H; Aburada M; Yokoi T; Kamataki T
Xenobiotica; 1993 Jan; 23(1):5-10. PubMed ID: 8484262
[TBL] [Abstract][Full Text] [Related]
19. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.
Meikle I; Cummings J; Macpherson JS; Hadfield JA; Smyth JF
Biochem Pharmacol; 1995 Jun; 49(12):1747-57. PubMed ID: 7598737
[TBL] [Abstract][Full Text] [Related]
20. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Bouscarel B; Matsuzaki Y; Ceryak S; Kudoh S; Fromm H
Int J Cancer; 1999 Nov; 83(4):491-6. PubMed ID: 10508485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
